Method for detecting imatinib metabolite in plasma of GIST patient based on non-targeted metabonomics

A metabolomics, non-targeting technology, applied in the field of biomedicine, can solve problems such as difficult to achieve analysis results, and achieve the effects of comprehensive material, high sensitivity, and high accuracy of statistical results

Active Publication Date: 2021-09-17
SICHUAN CANCER HOSPITAL
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complexity of plasma metabolites, traditional analy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting imatinib metabolite in plasma of GIST patient based on non-targeted metabonomics
  • Method for detecting imatinib metabolite in plasma of GIST patient based on non-targeted metabonomics
  • Method for detecting imatinib metabolite in plasma of GIST patient based on non-targeted metabonomics

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] A method for detecting imatinib metabolites in plasma of GIST patients based on non-targeted metabolomics, comprising the following steps:

[0079] 1. Sample collection and classification

[0080] In this study, a total of 40 GIST patients who did not take IM and took IM regularly for a long time were included. The ratio of the number of patients who did not take IM and the patients who took IM regularly for a long time was 1:3. Immediately and gently upside down 8 times to mix the anticoagulant and blood evenly (gently to avoid hemolysis), transfer to the laboratory smoothly and quickly, centrifuge at 5000r / min at room temperature for 5min, take 300uL supernatant and transfer to a clean EP tube , and stored in a -80°C refrigerator for testing.

[0081] As shown in Table 1, the plasma samples were numbered 1-40, and the IM blood drug concentrations in the numbered plasma samples were analyzed sequentially by two-dimensional liquid chromatography. According to the measu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for detecting imatinib metabolite in plasma of GIST patients based on non-targeted metabonomics, which comprises the following steps: collecting peripheral venous blood of a plurality of GIST patients who do not take IM or take IM regularly for a long time, processing the peripheral venous blood, performing non-targeted detection on a sample to be detected by adopting a UPLC-QTOF/MS (Ultra Performance Liquid Chromatography-Quadrature Time of Flight/Mass Spectrometry) combined technology to obtain original data of the metabolite in the plasma, performing unsupervised principal component analysis (PCA), orthogonal partial least squares discriminant analysis (OPLS-DA), Student's t-test and difference multiple analysis (FoldChange) on original data, searching differential metabolites, and searching a database to qualitatively determine the GIST metabolic marker. Technical support is provided for effective treatment of GIST patients suitable for IM treatment, and a foundation can be laid for effectiveness, pertinence, noninvasive screening and marker characterization of drug treatment after confirmation of digestive tract tumors.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a method for detecting imatinib metabolites in plasma of GIST patients based on non-targeted metabolomics. Background technique [0002] Gastrointestinal stromal tumors (Gastrointestinal Stromal Tumors, GIST) are the most common mesenchymal tumors of the digestive tract, accounting for about 0.3%-1% of gastrointestinal tumors, and its incidence tends to be younger. Imatinib mesylate (imatinib, IM) is a tyrosinase (TKIs) inhibitor, which has a good effect on inhibiting c-Kit activity, and it is used as a targeted drug in the clinical treatment of GIST. Remarkable achievements have been made in resectable intermediate-to-high-risk and unresectable, recurrent, metastatic or advanced GIST patients. Studies have found that IM, as an oral small-molecule targeted drug, has about 75% intra-individual variation and 60% inter-individual variation, and about 80% of patients develop secondary dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/06G01N30/72G01N30/86
CPCG01N30/02G01N30/06G01N30/72G01N30/8675G01N30/8696
Inventor 陈燕肖洪涛张蕊黄婷文丽王秋菊徐蓓
Owner SICHUAN CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap